TAXOL CHEMOTHERAPY

Taxol has shown to be a potent anticancer agent and has fuelled an intense research effort in recent years. It interferes with the multiplication of cancer cells and slows or stops their growth & spread in the body. Patients have so far been shown to tolerate Taxol better than other anti-cancer drugs used today, particularly due to it's relative non-toxicity. It provides a non intensive alternative to the more radical techniques of surgery and radiotherapy. The National Cancer Institute (NCI) has labelled Taxol as "the best anti-cancer agent developed in the last fifteen years".

CLINICAL TRIALS

Taxol entered clinical trials in 1983 and has since been approved by the US Food & Drug Administration (FDA) for use in treatment of Breast & Ovarian cancers. Taxol has shown a remarkable activity against resistant cases of advanced ovarian and breast cancers.

Taxol is currently in Clinical Trial Phase III. The results show far are as follows:-

The true potential of taxol in cancer therapy must await further experimentation and the completion of the clinical trials.

SIDE EFFECTS OF TAXOL

A more detailed account of the secondary action of Taxol is discussed in the section titled, 'Effects Of Taxol on the Cell'

The human 'side effects' attributed to Taxol Chemotherapy are as follows:-

Less common side effects:-

 


REFERENCES

http://www.bmi.net/mcaron/taxol.html

http://c267b.chor.ucl.ac.be/taxol.htm

Albert, B.; Bray, D.; Lewis, J.; Raff, M.; Roberts, K.; Watson, J.D. Molecular Biology of the Cell. 1996, 3rd edn, 802-804


NEXT PAGE